KbDNA
Empowering Life Science Research with Reagent Material Science

The inventiveness and commitment of the life sciences industry came to the forefront during the pandemic as it played a crucial role in developing vaccines through seamless collaboration between scientists, governments, healthcare systems, and regulators. Despite its growing significance, the domain follows an antiquated approach where researchers either use a traditional "add to cart" purchase or a generic re-ordering process to acquire vital clones and genetic sequences. A significant absence of material science know-how also hinders researchers from producing necessary reagents in house and compromises the research development timelines of life-saving products. This inefficient reagent acquisition approach and lack of material science expertise are driven by supply and manufacturing partners struggling to consistently maintain research-grade material standards while coping with the skyrocketing life sciences research endeavors.

Bridging this gap with its novel production technologies, automated data standardization with material science, and biotech solutions is kbDNA. Founded by Ed Hamdeh, kbDNA was deployed as an elaborate search engine platform with a comprehensive repository of reagents to help optimize the manufacturing of nucleotides and recombinant proteins.

"We offer a synthesis platform to address the limitations of life sciences industry's reagent acquisition process and introduce an innovative approach that drives versatile production and material science data automation for improved oligos and protein products," states Hamdeh, Principal Head of R&D, kbDNA.

The platform is powered by a diverse technical experience in nucleic acid chemistry that allows the integration of proprietary building block reagents to produce novel DNA and RNA oligos. This capability enables kbDNA to assist life science researchers in handling the growing demand for nucleic acids and protein biology.

It enhances research with short (oligo) and long nucleotide sequences that align with the end-users requirements and allows impactful chemical interventions at specific solid-phase production points. It also leverages its manufacturing expertise and unique benchmarking to equip research laboratories with synthetic bio reagents suitable for optimizing key experiments throughout early-to-late phase discovery and into preclinical scale.

kbDNA specializes in maintaining recombinant libraries to support researchers' bypass the problem of inconsistent analyte performance. A helpful example is the growing demand for soluble, functional, and stable receptors. The libraries source and analyze complex molecules that help researchers prioritize resourceful information and effectively sort reagents into suitable categories based on their designation or class (e.g., biomarkers, Infectious disease antigens, heat-shock proteins). Its libraries' automated relational data model drives the process development of customized production protocols consistent with a protein's biological profile.

kbDNA's flexibility to simultaneously act as a CRO and supplier helps it stand a class above its contemporaries in the life science space. It has a proven track record of upgrading conventional manufacturing systems cost effectively without compromising lead times. A case in point would be how kbDNA develops proteins and antibodies to meet decisive criteria such as reagent purity for emerging therapeutic companies. This helps kbDNA's clients use tailored reagents instead of compromising with ready-to-use proteins and antibodies that are not designed to be pulled off the shelf, modified, re-bottled, and shipped to researchers. kbDNA solves these impediments with its ability to efficiently package and send reagents of the required purity or similar criteria at a much lower cost. This capability has led numerous companies (both diagnostic and therapeutic) to approach kbDNA for their protein or antibody specifications.

Backed by a repository of solutions that optimize the manufacturing and implementation of bio-synthesis and its recombinant libraries, kbDNA is keen to re-introduce numerous molecules in nucleic acid and protein form reagents. Moving forward, kbDNA plans to continue utilizing its innovative approach and play a crucial role in advancing the development of novel therapeutics and innovative medical devices.

Here is the latest promo of our company - https://app.kbdna.com/hubfs/kbDNA%20Animation_Final_HQ.mp4